Status:
COMPLETED
18FDG-PET Imaging to Detect Changes in Airways Inflammation in Cystic Fibrosis Patients
Lead Sponsor:
The Hospital for Sick Children
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
6-18 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine if 18Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) imaging can detect changes in airways inflammation in Cystic Fibrosis (CF) patients after tre...
Detailed Description
Neutrophils play a key role in the pathogenesis of CF lung disease. We know that neutrophilic inflammation is related to a decline in pulmonary function. Therefore, early anti-inflammatory interventio...
Eligibility Criteria
Inclusion
- Diagnosis of CF as defined by two or more clinical features of CF and a documented sweat chloride \> 60mEq/L by quantitative pilocarpine iontophoresis test or a genotype showing two well characterized disease causing mutations
- Informed consent and verbal assent (as appropriate) provided by the subject's parent or legal guardian and the subject
- Ages 6-18 and able to perform reproducible spirometry
- Admission to the Hospital for Sick Children for a pulmonary exacerbation
Exclusion
- Inability to perform reproducible spirometry
- Diagnosis of Cystic Fibrosis Related Diabetes (CFRD)
- Medical instability that would preclude the ability to perform PET imaging
- FEV1% predicted \< 40%
- The use of supplementary oxygen
- Pregnancy or breastfeeding
- Severe claustrophobia
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00684346
Start Date
April 1 2008
End Date
April 1 2010
Last Update
October 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Hospital for Sick Children
Toronto, Ontario, Canada